CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $20.85 ($4,170,000)
- 8-K Event Regulation FD disclosure
- 144 Insider Sale of Securities
- 4 Shares withheld for taxes CFO gave up 1,235 shares (to pay taxes)
- 4 Shares withheld for taxes President & Immunovant CEO gave up 7,051 shares (to pay taxes)
- 4 Open-market sale Director sold 1,300,000 shares at an average $20.23 ($26,304,500)
- 4 Open-market sale Director sold 1,300,000 shares at an average $20.23 ($26,304,500)
- 4 Open-market sale Director by Deputization sold 1,300,000 shares at an average $20.23 ($26,304,500)
- 4 Open-market sale 10% owner sold 1,854,603 shares at an average $20.46 ($37,939,112)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Insider Changes in Ownership
- 144 Insider Sale of Securities
- 4 Insider Changes in Ownership
- 4 Insider Changes in Ownership
- 4 Insider Changes in Ownership
- 4 Insider Changes in Ownership
- 144 Insider Sale of Securities
Page 10 of 51 · 1,008 filings